MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2021.08.035

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2021

Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia.

Wang Shengmei, Liu Xuanjun, Wang Shengfeng, Ouyang Linqi, Li Hui, Ding Jinsong, Deng Guiming, Zhou Wenhu

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Discovery of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has revolutionized the therapy of chronic myeloid leukemia (CML), a malignant myeloproliferative disease characterized by abnormal activation of BCR-ABL fusion oncoprotein with protein tyrosine kinase (PTK) activity. However, the long-term treatment outcomes with TKIs are strongly limited by multiple drug resistances, resulting in relapse albeit with initial high response rate. Here, we reported a realgar (As4S4) nanocrystal-based delivery system to reverse drug resistance for synergistic CML therapy. While As4S4 is extremely insoluble in water, bovine serum albumin (BSA) was rationally screened to effectively stabilize As4S4 nanocrystal with uniformed size of ~40 nm. Imatinib (IMA), a representative TKIs, can be readily loaded into the hydrophobic domain of BSA to develop As4S4/IMA co-delivery system. Mechanistically, IMA inhibits PTK activity, while As4S4 degrades BCR-ABL1, which co-contribute to tumor suppression via complementary pathways for synergistic effect. Moreover, the nanosystem was modified with folic acid (FA) to enable tumor targetability, which has been demonstrated both in vitro and in vivo, resulting in robust tumor growth inhibition and significantly prolonged mice survival without any noticeable adverse effects. This work designed a synergistic nanoplatform for targeted CML therapy, provided a strategy to address the key limitation of As4S4 for biomedical applications, and highlighted the advantages of the combination between traditional Chinese and western medicine for diseases treatment.

Для цитирования: Wang Shengmei, Liu Xuanjun, Wang Shengfeng, Ouyang Linqi, Li Hui, Ding Jinsong, Deng Guiming, Zhou Wenhu. Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia.. Journal of controlled release : official journal of the Controlled Release Society. 2021. DOI: 10.1016/j.jconrel.2021.08.035.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.